share_log

复旦张江(688505.SH):奥贝胆酸片用于治疗原发性胆汁性胆管炎药品上市申请获得受理

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH): Obei cholic acid tablets for the treatment of primary biliary cholangitis pharmaceutical marketing application has been accepted.

Gelonghui Finance ·  Oct 31 03:40

On October 31st, shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (688505.SH) announced that its wholly-owned subsidiary, Taizhou Shanghai Fudan-Zhangjiang Pharmaceutical Co., Ltd., recently received the "Acceptance Notice" issued by the National Medical Products Administration for the domestic production pharmaceutical registration and listing application of Obecholic Acid Tablets (Specifications: 5mg, 10mg) (referred to as "the pharmaceutical") for the treatment of primary biliary cholangitis (PBC). The pharmaceutical belongs to the Farnesoid X receptor (FXR) agonist, FXR is a nuclear receptor highly expressed in the liver and intestine, playing a crucial role in bile acid metabolism regulation.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment